Latest News and Press Releases

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 Data...

Nipocalimab è il primo inibitore FcRn approvato per pazienti adulti e adolescenti affetti da gMG di età pari o superiore a 12 anni, che risultano positivi agli anticorpi anti-AChR o anti-MuSKNegli...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positiveIn the pivotal Phase 3 Vivacity-MG3 and Phase...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous...

Les réponses étaient rapides et durables, et une réduction tumorale a été observée chez 82 pour cent des patients1 Les nouveaux résultats issus de cette étude expérimentale s’appuient sur la solidité...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational study build on the strength of the data for amivantamab in...

Recommendation based on the findings from the Phase 3 ASTRO study in ulcerative colitis.1,2,3 Guselkumab has the potential to become the first IL-23 inhibitor to offer both subcutaneous and...

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK...

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3 studies that met all primary and co-primary endpoints....